Companies · Biotech / Pharma

Alto Pharmacy Holdings, Inc.

SAN FRANCISCO · Biotech / Pharma · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Alto Pharmacy Holdings, Inc. — recommendation, valuation, rhythm, risks.
$169.7M
Total raised · real
3
Rounds
3.6×
Latest step-up
Top 4%
Sector rank · raised
Series D+
Latest stage · inferred · Fri Jan 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Alto Pharmacy Holdings, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.61× the median modeled value of Series D+ Biotech / Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.5 yr ago; this sector typically re-raises about every 15 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Alto Pharmacy Holdings, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
5.5 yr record
Peak capital year was 2022 with $132.2M across 1 filings.
Market position
ahead of 97% of Biotech / Pharma peers
Capital scale is ahead of 97% of Biotech / Pharma peers; modeled value is above 99% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2022: $132.2M across 1 filings.
  • Largest single filing was $132.2M on 2022-01-14.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Alto Pharmacy Holdings, Inc. is one of 227 Biotech / Pharma companies tracked from SAN FRANCISCO. By capital raised it ranks among the largest (ahead of 97% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
18
Investors (latest)
2020
Year incorporated
2022-01-14
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeed · 2021-01-19 Raised $1.0M (real) Modeled valuation $32M (est)$1.0M$32MSeed2021Series B · 2021-10-18 Raised $36M (real) Modeled valuation $785M (est)$36M$785MSeries B2021Series D+ · 2022-01-14 Raised $132M (real) Modeled valuation $3.1B (est)$132M$3.1BSeries D+2022+$36M+$132MCumulative $170M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.0M · 2021
Series B$36.4M · 2021no Series A on file
Series D+$132.2M · 2022no Series C on file

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$3.1B
Base estimate est.
$614.2M
Conservative case
$5.7B
Upside case
$1.1B
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Seed · modeled $31.9M · 2021-01-192021Series B · modeled $785.0M · 2021-10-18Series D+ · modeled $3.1B · 2022-01-142022
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
70%
Survival probability
56% low · 77% high
1.37×/yr
Annual markup
1.53×/yr upside case
4.5 yr
Elapsed time used
4.5 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$172.1M/yr
Capital velocity
5.5 yr
On record since
2021
First round
3
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 30× above median
This company$169.7M
Sector median$5.6M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 2.6× above median
This company$132.2M
Sector median$51.0M
Modeled value — vs sector median (estimate, all stages) 102× above median
This company$3.1B
Sector median$30.5M

Raised more than 97% of sector peers (real $). Modeled value above 99% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 7.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Colossal Biosciences Inc. · Series D+ Raised $162.6M · modeled $2.8B (est)Vedanta Biosciences, Inc. · Series D+ Raised $240.3M · modeled $2.0B (est)Seismic Therapeutic, Inc. · Series D+ Raised $146.3M · modeled $1.9B (est)Vignette Bio, Inc. · Series D+ Raised $105.0M · modeled $1.1B (est)PharmaCann Inc. · Series D+ Raised $509.0M · modeled $413.5M (est)Ventyx Biosciences, Inc. · Series D+ Raised $192.3M · modeled $273.5M (est)Alto Pharmacy Holdings, Inc. (this company) Raised $169.7M · modeled $3.1B (est)Alto Pharmacy Holdings, Inc.
CompanyStageRaised · realValue · estvs peer med.
Alto Pharmacy Holdings, Inc. this companySeries D+$169.7M$3.1B1.61×
Colossal Biosciences Inc.Series D+$162.6M$2.8B1.43×
Vedanta Biosciences, Inc.Series D+$240.3M$2.0B1.01×
Seismic Therapeutic, Inc.Series D+$146.3M$1.9B1.00×
Vignette Bio, Inc.Series D+$105.0M$1.1B0.58×
PharmaCann Inc.Series D+$509.0M$413.5M0.21×
Ventyx Biosciences, Inc.Series D+$192.3M$273.5M0.14×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.0M2021-01-19$5.2M$31.9M90%
Series B$36.4M2021-10-18$202.4M$785.0M90%
Series D+$132.2M2022-01-14$1.1B$3.1B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.0M2021-01-19
    • First recorded raise — entered as Seed.
    • 18 investors on this round.
  2. Series B$36.4M2021-10-18
    • Came back fast: 9 mo vs the ~15 mo sector norm.
    • Round 34.9× larger than the prior — scaling up.
    • 7 investors on this round.
  3. Series D+$132.2M2022-01-14
    • Came back fast: 3 mo vs the ~15 mo sector norm.
    • Round 3.6× larger than the prior — scaling up.
    • 18 investors on this round.
Intelligence
2022 ~Q3
Modeled next raise · ~6mo cadence
$396.5M
Modeled next size est.range $257.8M$634.5M
3.6×
Last step-up
$172.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kevin Burns3 other2021-10
Neil Shah3 other2021-01
Nichola Eliovits3 other2021-01
ROBERT SPINNER3 other2021-01
James Karraker1 other2021-01
Mattieu Gamache-Asselin1 other2021-01
Nathaniel Kan2021-01
Registry & provenance

Alto Pharmacy Holdings, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1841543
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
ScriptDash Inc.OtherSeries D+$208.1M$2.2Bnetwork3 shared operators · same stage
Colossal Biosciences Inc.Biotech / PharmaSeries D+$162.6M$2.8Bsame sector · same stage
Greenlight Biosciences Inc.Biotech / PharmaSeries D+$179.4M$3.9Bsame sector · same stage
Ventyx Biosciences, Inc.Biotech / PharmaSeries D+$192.3M$273.5Msame sector · same stage
Seismic Therapeutic, Inc.Biotech / PharmaSeries D+$146.3M$1.9Bsame sector · same stage
Vedanta Biosciences, Inc.Biotech / PharmaSeries D+$240.3M$2.0Bsame sector · same stage
Vignette Bio, Inc.Biotech / PharmaSeries D+$105.0M$1.1Bsame sector · same stage
PharmaCann Inc.Biotech / PharmaSeries D+$509.0M$413.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Olive Pharmacy, LLCBiotech / PharmaPre-Seed$5.1M86%
Slate Bio, Inc.Biotech / PharmaSeed$29.9M85%
Gaingels Alto Pharmacy LLCBiotech / PharmaPre-Seed$9.5M84%
Palo Alto Health Sciences, Inc.HealthtechSeries B$166.2M84%
Teal Bio, Inc.Biotech / PharmaSeed$1.5M84%
Bond Biosciences, Inc.Biotech / PharmaSeries A$21.9M83%
Los Angeles Biosciences, Inc.Biotech / PharmaSeries A$16.4M83%
Alto Labs LLCPharmaceuticalsPre-Seed$704K83%
Frequently asked
How much funding has Alto Pharmacy Holdings, Inc. raised?
Alto Pharmacy Holdings, Inc. has raised approximately $169.7M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Alto Pharmacy Holdings, Inc.'s estimated valuation?
Provath's modeled valuation for Alto Pharmacy Holdings, Inc. is approximately $3.1B (modeled range $614.2M–$5.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Alto Pharmacy Holdings, Inc. at?
Alto Pharmacy Holdings, Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Fri Jan 14.
What does Alto Pharmacy Holdings, Inc. do and where is it based?
Alto Pharmacy Holdings, Inc. operates in the Biotech / Pharma sector, based in SAN FRANCISCO.
Explore related

See where Alto Pharmacy Holdings, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Alto Pharmacy Holdings, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.